Probiotics: do they help to control intestinal inflammation? (Q36631503)

15 August 2017

1 reference

title

Probiotics: do they help to control intestinal inflammation? (English)

1 reference

15 August 2017

0 references

Böhm SK

1

1 reference

PubMed ID

17057214

15 August 2017

Kruis W

series ordinal

2

1 reference

PubMed ID

17057214

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Annals of the New York Academy of Sciences

15 August 2017

1 reference

15 August 2017

1072

1 reference

15 August 2017

339-350

1 reference

Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease

15 August 2017

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Dysbiosis in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Probiotics in inflammatory bowel disease: is it all gut flora modulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Host-flora interactions in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Microbial-gut interactions in health and disease. Probiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Host-bacterial mutualism in the human intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Probiotics used in human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

[Methodological basis for the development of consensus recommendations]

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Treatment of ulcerative colitis using fecal bacteriotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Factors associated with ileal mucosal morphology and inflammation in patients with ileal pouch-anal anastomosis for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1326.005

1 reference

15 August 2017

1 reference

PubMed ID

17057214